|Free Dividend Report|
|Stock Splits Calendar|
|BIOD Stock Split History|
|Preferred Stock Newsletter|
|BIOD Options Chain|
|Stock Message Boards|
BIOD (BIOD) has 1 split in our BIOD split history database. The split for BIOD took place on June 12, 2012. This was a 1 for 4 reverse split, meaning for each 4 shares of BIOD owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as BIOD conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the BIOD split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BIOD shares, starting with a $10,000 purchase of BIOD, presented on a split-history-adjusted basis factoring in the complete BIOD split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-24.53%|
|Albireo Pharma is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes. Co.'s primary product candidate is a glucagon emergency management (GEM) drug-device combination that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. In addition to its GEM product, Co. is developing ultra-rapid-acting proprietary insulin formulations that are designed to be more rapid-acting for Type 1 and Type 2 diabetes patients. Also, Co. has used its proprietary excipients to develop pre-clinical analog-based ultra-rapid-acting insulin formulations using either insulin lispro or insulin aspart. According to our BIOD split history records, BIOD has had 1 split.|
|BIOD Split History Table|
|06/12/2012||1 for 4|
|Healthcare Stock Splits|
|BIOD is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|